RANCHO MIRAGE, Calif., Jan. 4, 2024 /PRNewswire/ -- Eisenhower Health is the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...

Ongoing long-term studies from the two major producers of transcatheter aortic valve replacements showed the minimally invasive route can continue to perform on par with open-heart surgery in a ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

Transcatheter aortic valve replacement (TAVR) is a procedure that can treat narrowing of the aortic valve in the heart. It involves an expandable replacement valve that helps improve blood flow. A ...

Edwards Lifesciences announced Thursday that the California company has completed three first-in-human implants of the company’s transcatheter mitral valve replacement system. But it is not the only ...

Please provide your email address to receive an email when new articles are posted on . Patients who underwent a second transcatheter aortic valve replacement had outcomes similar to those with a ...

Edwards Lifesciences, a medical technology company based in the US, has announced the complete acquisition of Innovalve Bio Medical, which specialises in transcatheter heart valve devices. The ...

SAN FRANCISCO, March 11 (Reuters) - Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...